Traders should monitor the 1H2026 NDA submission and 3Q2026 CHAPTER-3 topline data as primary catalysts; current financials are secondary. Cash runway appears sufficient for now, but future dilution risk increases if commercialization is delayed or approval denied.
Price Chart
Executive Summary
Pharvaris reported a narrow EPS beat of 3% ($-0.60 vs $-0.62 consensus) with no revenue, typical for a pre-revenue biotech. The focus remains on upcoming catalysts: NDA submission for deucrictibant IR in 1H2026 and topline data from the CHAPTER-3 pivotal trial in 3Q2026. Cash runway of €292M supports operations through key inflection points.
Key Financial Metrics
Key Facts
- EPS of $-0.60 vs. consensus of $-0.62 (3% beat), revenue $0 in line with expectations
- Cash and cash equivalents: €292 million as of December 31, 2025
- NDA submission for deucrictibant IR (on-demand HAE treatment) on track for 1H2026
- Topline data from CHAPTER-3 trial (prophylactic HAE treatment) expected in 3Q2026
- Enrollment ongoing in CREAATE trial for AAE-C1INH, a potential expansion indication
Financial Impact
Minimal near-term financial impact; company remains pre-revenue with expected losses continuing into 2026
Risk Factors
- Regulatory risk around NDA approval for deucrictibant IR in 2026
- Clinical risk in CHAPTER-3 and CREAATE trials failing to replicate RAPIDe-3 success
- Dilution risk if additional funding is needed beyond 2026
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3267207 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $38.06 $36.37 | ▲ +4.44% | ▲ +5.26% | $31.07 (+18.38%) |
Sep 14, 2026 17d ago | 144 | $38.06 $35.20 | ▼ −7.51% | ▼ −9.63% | $31.07 (−18.38%) |
Sep 14, 2026 18d ago | Insider Cluster | $38.86 $36.02 | ▼ −7.31% | ▼ −7.41% | $31.07 (−20.06%) |
Sep 11, 2026 21d ago | Insider Cluster | $38.02 $36.37 | ▼ −4.34% | ▼ −4.12% | $31.07 (−18.29%) |
Sep 8, 2026 24d ago | 6-K | $37.84 $38.86 | ▲ +2.70% | ▲ +3.36% | $31.07 (−17.90%) |
Aug 12, 2026 7w ago | 6-K | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 12, 2026 7w ago | Press Release | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 6, 2026 8w ago | Press Release | $34.45 $34.04 | ▼ −1.19% | ▼ −2.40% | $31.07 (−9.83%) |
Jul 6, 2026 12w ago | Press Release | $33.22 $35.07 | ▲ +5.57% | ▲ +5.08% | $31.07 (−6.49%) |
Jul 1, 2026 13w ago | Insider Cluster | $33.86 $35.96 | ▲ +6.20% | ▲ +5.27% | $31.07 (−8.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access